Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene (This gene does not contain this module)
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: MT-ND3

Summary for MT-ND3

Gene information	Gene symbol	MT-ND3
	Ensembl ID	ENSG00000198840
	Entrez ID	4537
	Gene name	NADH dehydrogenase subunit 3
	Synonyms	MTND3\|NAD3\|ND3
	Gene type	protein_coding
	UniProtAcc	P03897

Top

Dataset with differentially expressed gene: MT-ND3

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	1.10274	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.743715	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	3.78902	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.476184	3.19e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.300891	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.627787	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.399756	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.335453	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.506416	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.300462	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	-0.735088	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.713249	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.79393	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.465871	5.35e-11
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	-0.772088	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.803081	3.72e-33
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	pDCs	-0.565563	1.25e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.605146	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.465846	2.55e-31
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.293696	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.346204	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.276841	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	0.306624	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.495633	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	-0.540855	2.42e-18
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.406193	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.51863	6.89e-11
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.735436	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.328792	3.61e-17
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mast cells	1.00982	1.61e-05
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.469639	2.06e-08
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	0.430698	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	-0.501836	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.290082	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD4+ T cells	0.547341	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	Mono/Macro	0.309268	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	cDCs	0.259134	3.36e-02
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	0.515251	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	0.462788	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.749673	2.17e-26
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	0.520831	8.69e-05
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-1.34548	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	0.37783	5.48e-33
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	0.651948	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	0.260864	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	NK cells	0.270148	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	CD4+ T cells	0.340501	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	Plasma cells	0.467335	1.74e-05
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	pDCs	0.325043	1.42e-02
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	Mono/Macro	-0.300043	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.263457	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.300568	1.69e-06
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	0.923322	3.73e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.594425	2.25e-24
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	0.508421	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.752506	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.56819	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.515354	2.26e-24
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.990052	1.15e-42
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.884218	1.05e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.275227	2.17e-15
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.25195	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	-0.45732	3.64e-23
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.674673	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	cDCs	-0.580285	2.44e-07
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	-0.339311	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.775264	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	-0.531502	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	-0.665497	3.13e-27
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.810101	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.649411	2.79e-22
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.858679	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	-0.503849	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.25308	1.42e-09
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.589587	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	-0.306653	3.56e-05
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD8+ T cells	0.630368	1.56e-24
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	NK cells	0.596179	1.23e-19
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD4+ T cells	0.549371	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	B cells	0.707096	1.20e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.607315	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.6913	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.261309	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.37346	2.35e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.422536	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.55132	1.30e-09
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.583327	4.26e-42
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.376735	1.14e-05
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	-0.638448	1.64e-24
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	0.287857	7.22e-16
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-1.11023	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.353543	3.43e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	0.326521	1.98e-02
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	0.328543	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.788507	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	0.578115	1.12e-28
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	0.507877	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.344706	6.72e-25
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	0.31512	2.87e-30
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	0.549156	5.13e-10
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	0.484892	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.866485	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.577946	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-1.15447	0.00e+00

Top

Expression of MT-ND3 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to MT-ND3

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating MT-ND3

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating MT-ND3

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
MT-ND3	"NADH"	DB00157	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."